Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02459899 · ClinicalTrials.gov registry record · Phase 2
Dose-ranging Study in Patients With Type 1 Diabetes Mellitus
A Phase 2 study, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 141
- Enrollment target
NCT02459899 is a Phase 2 study that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 141 participants.
The verdict
NCT02459899, a Phase 2 study, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 141 participants
- Enrollment target
Study Summary
The primary objective of this study was to define the dose leading to desirable efficacy, as measured by the change in hemoglobin A1C (A1C) between Baseline and Week 12.
Interventions
- DRUG Placebo
- DRUG Sotagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2015-07 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02459899
The ClinicalTrials.gov registry entry for NCT02459899 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lexicon Pharmaceuticals, which has 56 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02459899 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02459899 about?
NCT02459899 is a clinical study titled "Dose-ranging Study in Patients With Type 1 Diabetes Mellitus". The primary objective of this study was to define the dose leading to desirable efficacy, as measured by the change in hemoglobin A1C (A1C) between Baseline and Week 12.
What is the current status of trial NCT02459899?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 141 participants. The study started on 2015-07. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02459899?
The interventions under investigation include: Placebo (DRUG), Sotagliflozin (DRUG).
Who is sponsoring clinical trial NCT02459899?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.